The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices ...

Hidradenitis suppurativa is a lesion-causing inflammatory disorder that affects at least 1 in 100 people and is strongly ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they ...

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug ...

The CEO of Novo Nordisk is on Capitol Hill Tuesday to testify before a Senate committee about the high costs of its drugs ...

Novo Nordisk charges $969 per month for Ozempic in the U.S., compared ... they don't understand what happens with pricing a ...

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...